Values First Advisors Inc. reduced its stake in argenx SE (NASDAQ:ARGX – Free Report) by 34.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,194 shares of the company’s stock after selling 636 shares during the period. Values First Advisors Inc.’s holdings in argenx were worth $647,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its holdings in shares of argenx by 49.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,504,506 shares of the company’s stock worth $2,167,235,000 after acquiring an additional 1,830,651 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of argenx by 24.8% in the first quarter. Janus Henderson Group PLC now owns 2,216,648 shares of the company’s stock worth $872,690,000 after acquiring an additional 439,889 shares during the period. Avoro Capital Advisors LLC boosted its holdings in shares of argenx by 0.3% in the first quarter. Avoro Capital Advisors LLC now owns 1,238,467 shares of the company’s stock worth $487,609,000 after acquiring an additional 3,900 shares during the period. Clearbridge Investments LLC boosted its holdings in shares of argenx by 3.6% in the second quarter. Clearbridge Investments LLC now owns 617,466 shares of the company’s stock worth $265,535,000 after acquiring an additional 21,189 shares during the period. Finally, Sei Investments Co. boosted its holdings in shares of argenx by 15.2% in the second quarter. Sei Investments Co. now owns 381,544 shares of the company’s stock worth $164,079,000 after acquiring an additional 50,477 shares during the period. 60.32% of the stock is owned by institutional investors.
argenx Price Performance
NASDAQ ARGX opened at $551.15 on Friday. The stock has a market capitalization of $32.76 billion, a PE ratio of -97.38 and a beta of 0.63. argenx SE has a 1 year low of $327.73 and a 1 year high of $571.97. The business’s 50-day moving average is $534.21 and its 200 day moving average is $458.10.
Analysts Set New Price Targets
ARGX has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. increased their price objective on argenx from $500.00 to $640.00 and gave the stock an “overweight” rating in a research report on Friday, August 23rd. HC Wainwright increased their price objective on argenx from $504.00 to $533.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Raymond James reiterated a “strong-buy” rating and issued a $605.00 price objective on shares of argenx in a research report on Thursday, October 10th. Deutsche Bank Aktiengesellschaft downgraded argenx from a “buy” rating to a “hold” rating in a research report on Friday, October 4th. Finally, Robert W. Baird raised their price target on argenx from $490.00 to $515.00 and gave the company an “outperform” rating in a research report on Monday, July 29th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, argenx currently has an average rating of “Moderate Buy” and an average price target of $550.44.
Read Our Latest Analysis on ARGX
About argenx
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
See Also
- Five stocks we like better than argenx
- What Investors Need to Know to Beat the Market
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Profitably Trade Stocks at 52-Week Highs
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- The Significance of Brokerage Rankings in Stock Selection
- Tesla Stock: Buy the Dips, Sell the Rips
Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenx SE (NASDAQ:ARGX – Free Report).
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.